Opinion ID: 4277712
Heading Depth: 3
Heading Rank: 1

Heading: A compound in the R configuration having the

Text: formula: wherein Ar is phenyl which is unsubstituted or substi- tuted with at least one halo group; Q is lower alkoxy, and Q1 is methyl. UCB, INC. v. ACCORD HEALTHCARE, INC. 13 8. The compound according to claim 1 which is (R) N-Benzyl 2-Acetamido-3-methoxypropionamide. 9. The compound according to claim 8 which con- tains at least 90% (w/w) R stereoisomer. 10. A therapeutic composition comprising an anticonvulsant effective amount of a compound ac- cording to any one of claims 1–9 and a pharmaceutical carrier therefor. 11. A method of treating central nervous system disorders in an animal comprising administering to said animal in need thereof an anticonvulsant effective amount of a compound according to any one of claims 1–9. 12. The method according to claim 11 wherein the animal is a mammal. 13. The method according to claim 12 wherein the mammal is a human. Claim 9 recites the lacosamide compound with 90% or greater purity. For its R positions, lacosamide has an unsubstituted benzyl at R, an unsubstituted methyl at R1, and a nonaromatic methoxymethyl group at R3.2